← All episodes

The Statin Paradox: Why This Drug Doesn't Help Most Patients

| 3 products mentioned
Mark Hyman, MD Mark Hyman, MD host
Watch on YouTube cardiovascular health statin therapy cholesterol management insulin resistance metabolic dysfunction lifestyle medicine medical skepticism

Dr. Mark Hyman challenges the widespread prescription of statins by examining clinical trial data showing they provide little to no benefit for patients with normal triglycerides and HDL cholesterol levels—even those who have already had heart attacks. Rather than LDL cholesterol alone, Hyman argues that insulin resistance, triglyceride-to-HDL ratios, and particle size are the true drivers of cardiovascular disease risk, and that statin side effects and lack of mortality reduction in many populations warrant a more personalized, lifestyle-first approach to heart health.

Key takeaways
  • • A large study of 231,000 heart attack patients found that 75% had normal LDL cholesterol levels, suggesting LDL is not the primary driver of cardiovascular events the way mainstream medicine assumes.
  • • Patients with normal triglycerides and HDL showed zero benefit from statins in clinical trials, even after experiencing heart attacks, indicating statins may only help a specific metabolic phenotype.
  • • The real cardiovascular risk markers are low HDL and high triglycerides (reflecting insulin resistance and small dense cholesterol particles), which are driven by sugar and starch intake rather than dietary fat.
  • • 20-50% of statin patients experience side effects including muscle pain, fatigue, brain fog, and erectile dysfunction, and many stop taking the medication within a few years—yet these harms are rarely weighed against marginal benefits.
  • • Hyman advocates for shared decision-making with patients rather than paternalistic prescription, empowering them to understand their actual cardiovascular risk before taking long-term medications with quality-of-life trade-offs.
  • • Genetic variation matters: some people are "lean mass hyperresponders" who may be harmed by high saturated fat intake or have familial hypercholesterolemia requiring different strategies than the general population.

Mentioned (3)

PCSK9 inhibitors "there's a use for the PCSK9 inhibitors there's a use for the new CTP drugs that are coming out th..." ▶ 7:41
CTP drugs "there's a use for the PCSK9 inhibitors there's a use for the new CTP drugs that are coming out th..." ▶ 7:43
carnivore diet "I've seen for example a patient on a carnivore diet who actually had something like that and when..." ▶ 9:25

More from these creators

Breast Implants Are Making Women Sick—Here's What's Happening

Mark Hyman, MD · Apr 01, 2026 · 10 recs

The Real Reason Endometriosis Keeps Coming Back | Dr. Mark Hyman & Dr. Elizabeth Boham

Mark Hyman, MD · Mar 30, 2026

Your Baby's Metabolism is Being Decided Right Now | Jessie Inchauspé

Mark Hyman, MD · Mar 25, 2026 · 6 recs

Your Body Is Storing Toxins Right Now—Here's What Happens

Mark Hyman, MD · Mar 23, 2026 · 8 recs

The Skill No One Teaches Us About Love | Baya Voce & Dr. Mark Hyman

Mark Hyman, MD · Mar 18, 2026 · 1 rec

IVF Isn't Fixing Fertility – Here's What Actually Works

Mark Hyman, MD · Mar 11, 2026 · 7 recs